• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病合并慢性肾脏病患者的最佳药物剂量。

Optimal medication dosing in patients with diabetes mellitus and chronic kidney disease.

机构信息

Sun Life Financial Professor of Wellness and Diabetes Education, Banting and Best Diabetes Centre, Faculty of Medicine and Assistant Professor, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.

出版信息

Can J Diabetes. 2014 Oct;38(5):334-43. doi: 10.1016/j.jcjd.2014.04.006.

DOI:10.1016/j.jcjd.2014.04.006
PMID:25284697
Abstract

Diabetes mellitus is the leading cause of chronic kidney disease (CKD) in Canada. As rates of diabetes rise, so does the prevalence of CKD. Diabetes and CKD are chronic diseases that require multiple medications for their management. Many of the anticipated effects of these medications are altered by the physiologic changes that occur in CKD. Failure to individualize drug dosing in this population may lead to toxicity or decreased therapeutic response, leading to treatment failure. At times this can be challenging for a multitude of reasons, including the limitations of available calculations for estimating renal function, inconsistent dosing recommendations and the lack of dosing recommendations for some medications. Clinicians caring for these patients need to consider an approach of individualized drug therapy that will ensure optimal outcomes. The better understanding that clinicians have of these challenges, the more effective they will be at using the available information as a guide together with their own professional judgement to make appropriate dosing changes. This article discusses the following: 1) physiologic changes that occur in CKD and its impact on drug dosing; 2) advantages and disadvantages of various calculations used for estimating renal function; 3) pharmacokinetic and pharmacodynamic changes of some commonly used medications in diabetes, and finally, 4) an approach to individualized drug dosing for this patient population.

摘要

糖尿病是加拿大慢性肾脏病(CKD)的主要病因。随着糖尿病发病率的上升,CKD 的患病率也随之上升。糖尿病和 CKD 是慢性病,需要多种药物来治疗。这些药物的许多预期作用都会被 CKD 引起的生理变化所改变。如果不对该人群进行个体化药物剂量调整,可能会导致药物毒性或治疗反应降低,从而导致治疗失败。由于多种原因,有时这可能具有挑战性,包括用于估计肾功能的可用计算方法的局限性、剂量建议不一致以及某些药物缺乏剂量建议。治疗这些患者的临床医生需要考虑个体化药物治疗方法,以确保最佳疗效。临床医生对这些挑战的了解越深入,他们就越能有效地利用现有信息,并结合自己的专业判断,做出适当的剂量调整。本文讨论了以下内容:1)CKD 中发生的生理变化及其对药物剂量的影响;2)用于估计肾功能的各种计算方法的优缺点;3)一些常用于糖尿病的药物的药代动力学和药效学变化,最后,4)针对该患者群体的个体化药物剂量调整方法。

相似文献

1
Optimal medication dosing in patients with diabetes mellitus and chronic kidney disease.糖尿病合并慢性肾脏病患者的最佳药物剂量。
Can J Diabetes. 2014 Oct;38(5):334-43. doi: 10.1016/j.jcjd.2014.04.006.
2
Incretin-based therapy in chronic kidney disease.基于肠降血糖素的治疗在慢性肾脏病中的应用。
Adv Chronic Kidney Dis. 2010 Sep;17(5):439-49. doi: 10.1053/j.ackd.2010.06.003.
3
Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease.口服降糖药在慢性肾脏病 2 型糖尿病患者中的应用。
Hormones (Athens). 2013 Oct-Dec;12(4):483-94. doi: 10.14310/horm.2002.1436.
4
Oral antidiabetics use among diabetic type 2 patients with chronic kidney disease. Do nephrologists take account of recommendations?2型糖尿病合并慢性肾脏病患者口服降糖药的使用情况。肾科医生是否考虑了相关建议?
J Diabetes Complications. 2016 May-Jun;30(4):675-80. doi: 10.1016/j.jdiacomp.2016.01.016. Epub 2016 Jan 22.
5
Hypoglycemia, chronic kidney disease, and diabetes mellitus.低血糖症、慢性肾脏病和糖尿病。
Mayo Clin Proc. 2014 Nov;89(11):1564-71. doi: 10.1016/j.mayocp.2014.07.013. Epub 2014 Oct 11.
6
Selection and dosing of medications for management of diabetes in patients with advanced kidney disease.晚期肾病患者糖尿病治疗药物的选择与剂量确定
Semin Dial. 2010 Mar-Apr;23(2):163-8. doi: 10.1111/j.1525-139X.2010.00703.x. Epub 2010 Feb 22.
7
Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: prevalence and prescription of antidiabetic drugs.瑞士初级保健医生随访的2型糖尿病患者中的慢性肾脏病:抗糖尿病药物的患病率及处方情况
Swiss Med Wkly. 2016 Feb 28;146:w14282. doi: 10.4414/smw.2016.14282. eCollection 2016.
8
Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease.胰岛素和口服降糖药物在糖尿病合并晚期肾病患者中的应用。
Semin Dial. 2004 Sep-Oct;17(5):365-70. doi: 10.1111/j.0894-0959.2004.17346.x.
9
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.卡格列净治疗2型糖尿病合并慢性肾脏病患者52周的疗效与安全性
Diabetes Obes Metab. 2014 Oct;16(10):1016-27. doi: 10.1111/dom.12348. Epub 2014 Jul 22.
10
Antidiabetic drug use trends in patients with type 2 diabetes mellitus and chronic kidney disease: A cross-sectional analysis of the National Health and Nutrition Examination Survey.2 型糖尿病合并慢性肾脏病患者的降糖药物使用趋势:基于全国健康和营养调查的横断面分析。
J Diabetes. 2020 May;12(5):385-395. doi: 10.1111/1753-0407.13003. Epub 2019 Nov 22.

引用本文的文献

1
Therapeutic Silencing of Centromere Protein X Ameliorates Hyperglycemia in Zebrafish and Mouse Models of Type 2 Diabetes Mellitus.着丝粒蛋白X的治疗性沉默改善2型糖尿病斑马鱼和小鼠模型中的高血糖症。
Front Genet. 2019 Jul 29;10:693. doi: 10.3389/fgene.2019.00693. eCollection 2019.
2
Development and Application of the GheOPS-Tool Addendum on Potentially Inappropriate Prescribing (PIP) of Renally Excreted Active Drugs (READs) in Older Adults with Polypharmacy.老年多重用药患者肾排泄活性药物(READs)潜在不适当处方(PIP)的GheOPS工具附录的开发与应用
Drugs Aging. 2018 Apr;35(4):343-364. doi: 10.1007/s40266-018-0530-x.
3
Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment.
利西那肽治疗 2 型糖尿病伴肾功能损害患者的疗效和安全性。
Diabetes Obes Metab. 2017 Nov;19(11):1594-1601. doi: 10.1111/dom.12986. Epub 2017 Jun 7.
4
Individualizing drug therapy in patients with diabetes and chronic kidney disease.糖尿病合并慢性肾脏病患者的个体化药物治疗
Can Pharm J (Ott). 2015 Sep;148(5):246-8. doi: 10.1177/1715163515600674.
5
Management of glycemia in diabetic patients with stage IV and V chronic kidney disease.IV期和V期慢性肾病糖尿病患者的血糖管理
Curr Diab Rep. 2015 May;15(5):25. doi: 10.1007/s11892-015-0600-y.